The development of adjuvant chemotherapy regimens generally takes into account the clinicopathologic characteristics of the tumor, patient-side factors and the patient’s wishes, as well as the possible benefits of chemotherapy and the adverse effects that may result from it. The prognosis is relatively poor for intermediate-stage breast cancer, which generally has a large tumor load, and after radical surgery, patients should receive the necessary postoperative adjuvant chemotherapy to prevent metastasis or recurrence. Many large clinical trials have confirmed that chemotherapy can lead to better treatment results and longer survival time for more patients with intermediate stage breast cancer compared to conservative treatment. Of course, chemotherapy should be chosen carefully if the patient is in early or mid-stage pregnancy. Chemotherapy is also not the recommended treatment for patients who are elderly and frail with severe visceral organic lesions.